Colorectal Cancer Characteristics and Outcomes after Solid Organ Transplantation.


Journal

Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537

Informations de publication

Date de publication:
2019
Historique:
received: 18 07 2018
revised: 09 12 2018
accepted: 06 02 2019
entrez: 4 4 2019
pubmed: 4 4 2019
medline: 4 4 2019
Statut: epublish

Résumé

Individuals after solid organ transplant may develop secondary malignancies. In our clinical practice, we noted an increasing number of individuals who developed colorectal cancers after solid organ transplantation. The primary aim of this study was to describe the characteristics and outcomes of the patients who developed colorectal cancer after solid organ transplant. Data was gathered and merged from several registries at Mayo Clinic to identify all patients who received a diagnosis of colon or rectal cancer and solid organ transplant. Continuous variables were summarized as mean (standard deviation) and median (range), while categorical variables were reported as frequency (percentage). Time to colorectal cancer after transplant and overall survival after cancer diagnosis were estimated using Kaplan-Meier method. Initially, 115 colorectal cancer patients who also had a transplant were identified. The diagnosis of colorectal cancer was noted after solid organ transplant in 63 patients. The mean age at transplant was 57 years. Majority had received a kidney transplant (44.4%) followed by liver (36.5%). The median time to develop colorectal cancer was 59.3 months (range: 4.4-251.4 months). 15 (24.6%) were stage 4 at diagnosis and 13 (21.3%) had stage 3 colorectal cancer. Median overall survival was 30.8 months; 5-, 10- and 15-year survival were noted to be 42.5%, 17.9%, and 7.5%, respectively. None of the stage 4 patients were alive at 5 years; 5-year survival rate for stage 1, 2, and 3 patients was 77%, 50%, and 42%, respectively. Our study reports on one of the largest cohorts of patients of colorectal cancer that developed the cancer after solid organ transplant. Survival is extremely poor for advanced cases. However, long-term survivors are noted who developed the cancer at a relatively early stage. Colorectal screening recommendations may need to be revised for patients after solid organ transplant.

Sections du résumé

BACKGROUND BACKGROUND
Individuals after solid organ transplant may develop secondary malignancies. In our clinical practice, we noted an increasing number of individuals who developed colorectal cancers after solid organ transplantation. The primary aim of this study was to describe the characteristics and outcomes of the patients who developed colorectal cancer after solid organ transplant.
MATERIALS AND METHODS METHODS
Data was gathered and merged from several registries at Mayo Clinic to identify all patients who received a diagnosis of colon or rectal cancer and solid organ transplant. Continuous variables were summarized as mean (standard deviation) and median (range), while categorical variables were reported as frequency (percentage). Time to colorectal cancer after transplant and overall survival after cancer diagnosis were estimated using Kaplan-Meier method.
RESULTS RESULTS
Initially, 115 colorectal cancer patients who also had a transplant were identified. The diagnosis of colorectal cancer was noted after solid organ transplant in 63 patients. The mean age at transplant was 57 years. Majority had received a kidney transplant (44.4%) followed by liver (36.5%). The median time to develop colorectal cancer was 59.3 months (range: 4.4-251.4 months). 15 (24.6%) were stage 4 at diagnosis and 13 (21.3%) had stage 3 colorectal cancer. Median overall survival was 30.8 months; 5-, 10- and 15-year survival were noted to be 42.5%, 17.9%, and 7.5%, respectively. None of the stage 4 patients were alive at 5 years; 5-year survival rate for stage 1, 2, and 3 patients was 77%, 50%, and 42%, respectively.
CONCLUSIONS CONCLUSIONS
Our study reports on one of the largest cohorts of patients of colorectal cancer that developed the cancer after solid organ transplant. Survival is extremely poor for advanced cases. However, long-term survivors are noted who developed the cancer at a relatively early stage. Colorectal screening recommendations may need to be revised for patients after solid organ transplant.

Identifiants

pubmed: 30941176
doi: 10.1155/2019/5796108
pmc: PMC6421000
doi:

Types de publication

Journal Article

Langues

eng

Pagination

5796108

Références

Lancet. 2000 May 27;355(9218):1886-7
pubmed: 10866449
Transpl Int. 2000;13 Suppl 1:S394-8
pubmed: 11112040
Transpl Int. 2000;13 Suppl 1:S402-5
pubmed: 11112042
J Hepatol. 2001 Jan;34(1):84-91
pubmed: 11211912
Br J Cancer. 2003 Oct 6;89(7):1221-7
pubmed: 14520450
Dis Colon Rectum. 2004 Nov;47(11):1898-903
pubmed: 15622583
Transpl Int. 2007 Jun;20(6):497-504
pubmed: 17343685
Colorectal Dis. 2010 Jul;12(7):657-66
pubmed: 19508543
Transplantation. 2009 Sep 15;88(5):706-10
pubmed: 19741469
Dis Colon Rectum. 2010 May;53(5):817-21
pubmed: 20389217
Am J Transplant. 2010 Apr;10(4):868-76
pubmed: 20420641
Inflamm Bowel Dis. 2012 Feb;18(2):269-74
pubmed: 21425212
Yonsei Med J. 2011 May;52(3):454-62
pubmed: 21488188
JAMA. 2011 Nov 2;306(17):1891-901
pubmed: 22045767
Transplant Proc. 2013 Apr;45(3):1102-5
pubmed: 23622637
J Gastrointest Surg. 2014 Mar;18(3):599-604
pubmed: 24254836
Liver Int. 2015 Jun;35(6):1748-55
pubmed: 25488375
Medicine (Baltimore). 2014 Dec;93(28):e310
pubmed: 25526480
Transplant Proc. 2015 Sep;47(7):2198-200
pubmed: 26361679
Transplantation. 2017 Aug;101(8):1859-1866
pubmed: 28272287
World J Gastroenterol. 2017 Feb 21;23(7):1224-1232
pubmed: 28275302
Am J Transplant. 2018 Apr;18(4):952-963
pubmed: 28925583
Turk J Gastroenterol. 2018 May;29(3):316-324
pubmed: 29755016
Br Med J. 1968 Dec 21;4(5633):746-8
pubmed: 4881420
Transplant Proc. 1969 Mar;1(1):106-12
pubmed: 4944206
Nephrol Dial Transplant. 1995;10 Suppl 1:74-80
pubmed: 7617285
Int J Cancer. 1995 Jan 17;60(2):183-9
pubmed: 7829213
Hematol Oncol Clin North Am. 1993 Apr;7(2):431-45
pubmed: 8468275
J Infect Dis. 1997 Dec;176(6):1462-7
pubmed: 9395355

Auteurs

Amit Merchea (A)

Division of Colon & Rectal Surgery, Mayo Clinic, Jacksonville, FL, USA.

Faisal Shahjehan (F)

Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.

Kristopher P Croome (KP)

Division of Colon & Rectal Surgery, Mayo Clinic, Jacksonville, FL, USA.

Jordan J Cochuyt (JJ)

Division of Biomedical Statistics & Informatics, Mayo Clinic, Jacksonville, FL, USA.

Zhuo Li (Z)

Division of Biomedical Statistics & Informatics, Mayo Clinic, Jacksonville, FL, USA.

Dorin T Colibaseanu (DT)

Division of Colon & Rectal Surgery, Mayo Clinic, Jacksonville, FL, USA.

Pashtoon Murtaza Kasi (PM)

Division of Hematology and Oncology, University of Iowa, Iowa City, IA, USA.

Classifications MeSH